SCYNEXIS (LTS:0L49) Cyclically Adjusted Book per Share: $35.93 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L49 SCYNEXIS Inc LTS:0L49
45 GF Score
Price $5.27
GF Value $17.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Cyclically Adjusted Book per Share?

SCYNEXIS LTS:0L49 +8.49% 45 Cyclically Adjusted Book per Share is $35.93 as of Jun. 2026. GuruFocus rates LTS:0L49 with a GF Score™ of 45/100 and a GF Value™ of $17.91 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

SCYNEXIS's adjusted book value per share for the three months ended in Jun. 2026 was $6.727. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $35.93 for the trailing ten years ended in Jun. 2026.

During the past 12 months, SCYNEXIS's average Cyclically Adjusted Book Growth Rate was -44.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of SCYNEXIS was 1.30% per year. The lowest was 1.30% per year. And the median was 1.30% per year.

As of today (2026-08-16), SCYNEXIS's current stock price is $5.2726. SCYNEXIS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $35.93. SCYNEXIS's Cyclically Adjusted PB Ratio of today is 0.15.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of SCYNEXIS was 0.99. The lowest was 0.08. And the median was 0.15.


SCYNEXIS  (LTS:0L49) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SCYNEXIS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.2726/35.93
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of SCYNEXIS was 0.99. The lowest was 0.08. And the median was 0.15.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


SCYNEXIS Cyclically Adjusted Book per Share Related Terms


SCYNEXIS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS Cyclically Adjusted Book per Share Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 5.46 9.10 9.58 5.58

SCYNEXIS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.90 6.95 5.58 4.83 35.93

LTS:0L49 vs IXHL, ETST, INIS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Cyclically Adjusted PB Ratio falls into.


LTS:0L49
45GF Score
SCYNEXIS Inc LTS:0L49
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SCYNEXIS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SCYNEXIS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.727/333.9520*333.9520
=6.727

Current CPI (Jun. 2026) = 333.9520.

SCYNEXIS Quarterly Data

Book Value per Share CPI Adj_Book
201609 113.229 241.428 156.622
201612 113.049 241.432 156.371
201703 105.119 243.801 143.989
201706 95.637 244.955 130.384
201709 77.017 246.819 104.206
201712 59.144 246.524 80.119
201803 62.874 249.554 84.138
201806 45.312 251.989 60.050
201809 47.253 252.439 62.511
201812 52.042 251.233 69.177
201903 18.041 254.202 23.701
201906 15.252 256.143 19.885
201909 8.568 256.759 11.144
201912 10.587 256.974 13.758
202003 5.278 258.115 6.829
202006 4.834 257.797 6.262
202009 7.080 260.280 9.084
202012 9.259 260.474 11.871
202103 10.056 264.877 12.678
202106 11.172 271.696 13.732
202109 12.597 274.310 15.336
202112 11.499 278.802 13.774
202203 10.656 287.504 12.378
202206 11.161 296.311 12.579
202209 4.216 296.808 4.744
202212 0.791 296.797 0.890
202303 -7.181 301.836 -7.945
202306 20.030 305.109 21.924
202309 19.796 307.789 21.479
202312 15.687 306.746 17.078
202403 15.694 312.332 16.780
202406 12.765 314.175 13.569
202409 12.340 315.301 13.070
202412 11.602 315.605 12.276
202503 10.359 319.799 10.817
202506 9.080 322.561 9.401
202509 6.946 324.800 7.142
202512 9.071 324.054 9.348
202603 5.326 330.213 5.386
202606 6.727 333.952 6.727

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $35.93 mean?
SCYNEXIS (LTS:0L49) has a Cyclically Adjusted Book per Share of $35.93 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on SCYNEXIS and its competitors.
Is SCYNEXIS's Cyclically Adjusted Book per Share too high?
SCYNEXIS's current Cyclically Adjusted Book per Share is $35.93. Overall, SCYNEXIS has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Cyclically Adjusted Book per Share compare to IXHL and ETST?
SCYNEXIS's Cyclically Adjusted Book per Share of $35.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current Cyclically Adjusted Book per Share is $35.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (LTS:0L49) is currently considered Possible Value Trap. The stock's GF Value™ is $17.91, compared to a current price of $5.27 — trading 70.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is $35.93. SCYNEXIS's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For SCYNEXIS (LTS:0L49), the current Cyclically Adjusted Book per Share is $35.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (LTS:0L49) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of $5.27 is trading 70.6% below its estimated GF Value™ of $17.91. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for LTS:0L49:

  • Cyclically Adjusted Book per Share: $35.93
  • GF Value™: $17.91 vs. price of $5.27 (70.6% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the LTS:0L49 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SCYNEXIS Business Description

Other Exchanges SCYX:USA135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
45GF Score

Get the complete analysis for LTS:0L49

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price
$17.91
GF Value